

Helix BioMedix Shares to Be Quoted on OTCQB

HXBM Stock Price Quotation No Longer Available on OTCBB

Bothell, Washington — March 09, 2011 — Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that its common stock will be quoted exclusively on the OTCQB electronic platform and will no longer be available on the OTC Bulletin Board (OTCBB). More than 800 companies, including Helix BioMedix, have ceased to trade on the OTCBB in the past several weeks due to the departure of market makers from that platform.

The OTCQB is the middle tier for OTC-traded companies that are reporting with the U.S. Securities and Exchange Commission (SEC) or a U.S. banking or insurance regulator. Helix BioMedix's common stock has been quoted on the OTCQB since the inception of that tier in April 2010 but previously traded concurrently on the OTCBB.

For the most accurate share price and trading activities for Helix BioMedix stock, please refer to www.otcmarkets.com. Some financial Web sites, such as Yahoo Finance and other trading platforms, may now report Helix BioMedix using different ticker symbol extensions than those previously utilized for the OTCBB. Please contact Helix BioMedix investor relations with any additional questions.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking[®], Cerakine[™], and SmartPeptide[™] are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Investor Contact:

Matt Kreps
Shelton Group Investor Relations
(972) 239-5119 X 125
mkreps@sheltongroup.com

Company Contact:

R. Stephen Beatty
President and CEO
(425) 402-8400
sbeatty@helixbiomedix.com